-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Maintains Buy on BioHarvest Sciences, Lowers Price Target to $8

Benzinga·08/12/2026 18:04:47
Listen to the news
Roth Capital analyst Sean McGowan maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowers the price target from $10 to $8.